However, in Western Europe, a slowdown,40 a decrease32,34 or a stabilization24,35 of genotype 3 prevalence have recently been reported
"If we're able to reduce weight and improve those risk factors, we're helping lower the chances of serious health complications down the road." Beyond heart health, obesity can also affect hormone production
GIP/GLP-1 receptor co-agonists The incretin hormone glucose-dependent insulinotropic polypeptide (GIP) was not initially adopted as a therapeutic because it loses glucose-lowering efficacy in type 2 diabetes [7, 49]
Researchers hope these therapies will provide: stronger appetite suppression increased fat burning improved insulin sensitivity greater energy expenditure more sustainable weight loss Several promising medications are currently in clinical development
Peptide-based therapies like CJC-1295 combined with Ipamorelin have become widely discussed in anti-aging, body-composition, and recovery communities